Paper41007627
Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.
Jin Y and 4 others. Biomedicines, 2025. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab. Papers, record 41007627. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007627
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References109
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26923204 | Plasma cells as an innovative target in autoimmune disease with renal manifestations. | Nat Rev Nephrol | 2016 | https://conductscience.org/library/papers/26923204 | PubMed |
| 2 | 35779372 | Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis. | Mult Scler Relat Disord | 2022 | https://conductscience.org/library/papers/35779372 | PubMed |
| 3 | 39966139 | Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies. | Pediatr Nephrol | 2025 | https://conductscience.org/library/papers/39966139 | PubMed |
| 4 | 38552841 | A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. | Kidney Int | 2024 | https://conductscience.org/library/papers/38552841 | PubMed |
| 5 | 21187443 | Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. | J Immunol | 2011 | https://conductscience.org/library/papers/21187443 | PubMed |
| 6 | 36071552 | Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. | Nephrol Dial Transplant | 2023 | https://conductscience.org/library/papers/36071552 | PubMed |
| 7 | 37777061 | Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series. | Am J Kidney Dis | 2024 | https://conductscience.org/library/papers/37777061 | PubMed |
| 8 | 39874224 | CD19-CAR T-cell therapy induces deep tissue depletion of B cells. | Ann Rheum Dis | 2025 | https://conductscience.org/library/papers/39874224 | PubMed |
| 9 | 36223961 | Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome. | BMJ Open | 2022 | https://conductscience.org/library/papers/36223961 | PubMed |
| 10 | 40052241 | The Role of IL-10-Producing Regulatory B Cells in Children With Primary Nephrotic Syndrome. | Nephrology (Carlton) | 2025 | https://conductscience.org/library/papers/40052241 | PubMed |
| 11 | 39431468 | Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. | J Am Soc Nephrol | 2025 | https://conductscience.org/library/papers/39431468 | PubMed |
| 12 | 35716094 | A critical role of the podocyte cytoskeleton in the pathogenesis of glomerular proteinuria and autoimmune podocytopathies. | Acta Physiol (Oxf) | 2022 | https://conductscience.org/library/papers/35716094 | PubMed |
| 13 | 34788412 | Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? | Rheumatology (Oxford) | 2022 | https://conductscience.org/library/papers/34788412 | PubMed |
| 14 | 35110735 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. | Nature | 2022 | https://conductscience.org/library/papers/35110735 | PubMed |
| 15 | 35354600 | Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. | J Am Soc Nephrol | 2022 | https://conductscience.org/library/papers/35354600 | PubMed |
| 16 | 40017729 | Obinutuzumab in membranous nephropathy: a potential game-changer in treatment. | Drugs Context | 2025 | https://conductscience.org/library/papers/40017729 | PubMed |
| 17 | 34094516 | Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. | Clin Kidney J | 2021 | https://conductscience.org/library/papers/34094516 | PubMed |
| 18 | 33091355 | Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. | Lancet Haematol | 2020 | https://conductscience.org/library/papers/33091355 | PubMed |
| 19 | 36137752 | Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients. | J Am Soc Nephrol | 2023 | https://conductscience.org/library/papers/36137752 | PubMed |
| 20 | 37842819 | Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis. | Expert Rev Neurother | 2023 | https://conductscience.org/library/papers/37842819 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42630345 | A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42630345 | PubMed |
| 42518347 | Clinical evaluation of rituximab combined with ACE inhibitors and statins in refractory nephrotic syndrome: associations with proteinuria, lipid profiles, and podocyte-related biomarkers. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42518347 | PubMed |
| 42495251 | Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025). | Front Pediatr | 2026 | https://conductscience.org/library/papers/42495251 | PubMed |
| 42491171 | Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42491171 | PubMed |
| 42414649 | Obinutuzumab as a primary anti-CD20 agent in pediatric frequently relapsing and steroid-dependent nephrotic syndrome. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42414649 | PubMed |
| 41659867 | B cells in acquired aplastic anemia and the exploratory role of rituximab: considerations in pediatric and female patients. | Front Immunol | 2026 | https://conductscience.org/library/papers/41659867 | PubMed |
| 41488676 | Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome: an extended follow-up. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488676 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007627
GET https://conductscience.org/api/papers/v1/41007627/references?page=2